Mirum Pharmaceuticals (FRA:08D) 5-Year EBITDA Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Mirum Pharmaceuticals 5-Year EBITDA Growth Rate?

Mirum Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2024 was €-0.30.

During the past 3 years, the average EBITDA Per Share Growth Rate was 6.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Mirum Pharmaceuticals was 7.30% per year. The lowest was 6.20% per year. And the median was 6.75% per year.

Competitive Comparison of Mirum Pharmaceuticals's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Mirum Pharmaceuticals's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mirum Pharmaceuticals's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Mirum Pharmaceuticals's 5-Year EBITDA Growth Rate falls into.

Mirum Pharmaceuticals 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Mirum Pharmaceuticals (FRA:08D) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Mirum Pharmaceuticals 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Mirum Pharmaceuticals's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Mirum Pharmaceuticals (FRA:08D) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirum Pharmaceuticals Inc (FRA:08D) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

MIRM:USA MIRM:Mexico

Address

950 Tower Lane, Suite 1050, Foster City, CA, USA, 94404

Website

https://www.mirumpharma.com

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Mirum Pharmaceuticals (FRA:08D) Headlines

No Headlines